Pfizer vs Grok
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
About
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.